The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1634
October 4, 2021
View Complete Issue         Table of Contents 2019 
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
October 4, 2021 (Issue: 1634)
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate (Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
Article code: 1634b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.